Nifty

:

22795.90

Sensex

:

75311.06

-117.25 (-0.51%)
-424.90 (-0.56%)

Login

Nifty
Sensex

:
:

22795.90
75311.06

-117.25 (-0.51%)
-424.90 (-0.56%)

Supriya Lifescience Ltd.

Pharmaceuticals & Drugs

Rating :

N/A

BSE: 543434 | NSE: SUPRIYA

Watchlist

NSE BSE

752.90

06-Feb-2025

Open
High
Low
Previous Close

769.75
776.90
746.10
769.75

Volume
Traded Value (lacs)
52 Week High
52 Week Low

248275
1883.76
835.20
305.50

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

5,180.68
29.69
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

5,096.36
0.12%
5.44

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

15.26
12.85
2.47

EBITDA CAGR (%)

10 Years
5 Years
3 Years

26.19
12.30
-3.87

PAT CAGR (%)

10 Years
5 Years
3 Years

30.67
10.17
-7.77

P:E (Median)

8 Years
5 Years
3 Years

-
-
23.09

P:BV (Average)

8 Years
5 Years
3 Years

-
-
3.85

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
14.72

Earnings Forecasts:

Description 2024 2025 2026 2027
Adj EPS 14.8
P/E Ratio 53.23
Revenue 570
EBITDA 173
Net Income 119
ROA 13.7
P/Bk Ratio 7.78
ROE 15.73
FCFF -22.32
FCFF Yield -0.36

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var% Mar 24 Mar 23 Var%
Net Sales 185.65 140.07 32.54% 166.10 140.09 18.57% 160.63 132.02 21.67% 158.18 142.27 11.18%
Expenses 119.70 98.59 21.41% 101.39 108.34 -6.41% 98.08 87.53 12.05% 102.68 87.22 17.73%
EBITDA 65.95 41.49 58.95% 64.72 31.75 103.84% 62.54 44.49 40.57% 55.50 55.05 0.82%
EBIDTM 35.53% 29.62% 38.96% 22.66% 38.94% 33.70% 35.09% 38.69%
Other Income 2.10 3.06 -31.37% 2.52 2.47 2.02% 2.22 2.92 -23.97% 2.19 1.96 11.73%
Interest 0.51 0.49 4.08% 0.43 0.46 -6.52% 0.34 0.82 -58.54% 0.60 0.71 -15.49%
Depreciation 4.96 3.96 25.25% 4.74 3.98 19.10% 4.66 3.95 17.97% 3.91 3.01 29.90%
PBT 62.58 40.10 56.06% 62.06 29.78 108.39% 59.77 42.64 40.17% 53.17 53.29 -0.23%
Tax 15.80 10.31 53.25% 15.92 5.89 170.29% 15.13 14.13 7.08% 16.24 15.06 7.84%
PAT 46.78 29.79 57.03% 46.15 23.88 93.26% 44.64 28.51 56.58% 36.93 38.23 -3.40%
PATM 25.20% 21.27% 27.78% 17.05% 27.79% 21.60% 23.35% 26.87%
EPS 5.81 3.70 57.03% 5.73 2.97 92.93% 5.55 3.54 56.78% 4.59 4.75 -3.37%

Description Sep 24 Sep 23 Var% Jun 24 Jun 23 Var% Mar 24 Mar 23 Var% Dec 23 Dec 22 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Right to Left

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 670.56 570.37 460.94 530.05 391.22 311.64 277.84 212.91 183.50 170.66 137.87 Net Sales Growth 20.94% 23.74% -13.04% 35.49% 25.54% 12.17% 30.50% 16.03% 7.52% 23.78% Cost Of Goods Sold 214.62 221.74 180.81 195.80 128.13 138.48 146.87 135.50 122.98 107.43 88.28 Gross Profit 455.94 348.63 280.13 334.24 263.09 173.16 130.96 77.41 60.52 63.22 49.59 GP Margin 67.99% 61.12% 60.77% 63.06% 67.25% 55.56% 47.14% 36.36% 32.98% 37.04% 35.97% Total Expenditure 421.85 394.68 332.50 316.06 218.07 213.26 213.41 190.96 166.38 151.00 120.71 Power & Fuel Cost - 21.37 20.95 14.07 9.24 8.97 8.06 7.03 6.93 6.64 5.25 % Of Sales - 3.75% 4.55% 2.65% 2.36% 2.88% 2.90% 3.30% 3.78% 3.89% 3.81% Employee Cost - 67.64 55.58 49.08 32.76 25.59 18.97 16.30 12.61 10.48 9.29 % Of Sales - 11.86% 12.06% 9.26% 8.37% 8.21% 6.83% 7.66% 6.87% 6.14% 6.74% Manufacturing Exp. - 34.03 28.71 20.01 14.05 15.29 18.59 14.36 9.35 5.82 3.91 % Of Sales - 5.97% 6.23% 3.78% 3.59% 4.91% 6.69% 6.74% 5.10% 3.41% 2.84% General & Admin Exp. - 21.66 16.73 11.05 8.76 9.08 6.92 8.02 8.17 10.14 4.47 % Of Sales - 3.80% 3.63% 2.08% 2.24% 2.91% 2.49% 3.77% 4.45% 5.94% 3.24% Selling & Distn. Exp. - 23.51 24.16 22.56 23.12 13.72 11.54 9.18 2.84 3.55 3.04 % Of Sales - 4.12% 5.24% 4.26% 5.91% 4.40% 4.15% 4.31% 1.55% 2.08% 2.20% Miscellaneous Exp. - 4.73 5.56 3.49 2.02 2.12 2.45 0.57 3.50 6.93 3.04 % Of Sales - 0.83% 1.21% 0.66% 0.52% 0.68% 0.88% 0.27% 1.91% 4.06% 4.69% EBITDA 248.71 175.69 128.44 213.99 173.15 98.38 64.43 21.95 17.12 19.66 17.16 EBITDA Margin 37.09% 30.80% 27.86% 40.37% 44.26% 31.57% 23.19% 10.31% 9.33% 11.52% 12.45% Other Income 9.03 10.96 9.94 7.58 5.00 11.07 8.33 8.59 7.45 2.39 2.41 Interest 1.88 5.15 3.08 4.20 4.08 6.85 10.22 10.75 11.76 10.04 6.92 Depreciation 18.27 15.81 11.81 10.12 6.76 6.38 5.43 5.33 4.75 3.95 2.49 PBT 237.58 165.69 123.49 207.24 167.31 96.23 57.10 14.46 8.06 8.06 10.16 Tax 63.09 46.58 33.63 55.44 43.72 22.82 17.68 5.74 2.40 2.37 1.95 Tax Rate 26.56% 28.11% 27.23% 26.75% 26.13% 23.71% 30.96% 39.70% 29.78% 29.40% 19.19% PAT 174.50 119.11 89.86 151.81 123.59 73.40 39.42 8.73 5.66 5.69 8.21 PAT before Minority Interest 174.50 119.11 89.86 151.81 123.59 73.40 39.42 8.73 5.66 5.69 8.21 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 26.02% 20.88% 19.49% 28.64% 31.59% 23.55% 14.19% 4.10% 3.08% 3.33% 5.95% PAT Growth 44.92% 32.55% -40.81% 22.83% 68.38% 86.20% 351.55% 54.24% -0.53% -30.69% EPS 21.68 14.80 11.16 18.86 15.35 9.12 4.90 1.08 0.70 0.71 1.02

Results Balance Sheet

Standalone Figures in Rs. Crores

Right to Left

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 815.37 699.46 615.69 268.58 149.19 93.79 54.66 45.89 41.72 37.38 Share Capital 16.10 16.10 16.10 14.64 14.64 14.64 14.64 14.64 14.64 4.88 Total Reserves 799.27 683.36 599.59 253.95 134.56 79.15 40.02 31.25 26.04 32.51 Non-Current Liabilities 28.98 25.04 19.38 30.86 31.85 24.36 44.86 51.30 39.21 23.35 Secured Loans 0.00 0.00 0.00 0.00 2.39 8.14 35.33 43.78 30.57 16.94 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.62 3.84 2.73 Long Term Provisions 0.80 5.88 2.93 1.30 1.03 0.69 0.58 0.00 0.00 0.00 Current Liabilities 79.57 95.78 99.70 146.02 155.39 134.91 145.88 144.15 150.26 114.88 Trade Payables 59.57 64.23 48.97 51.02 49.39 44.13 41.75 40.69 49.79 29.85 Other Current Liabilities 19.64 9.50 22.61 11.48 25.67 8.24 14.82 5.94 4.21 3.99 Short Term Borrowings 0.00 16.63 21.30 67.41 76.68 77.21 85.74 94.67 94.69 79.08 Short Term Provisions 0.37 5.42 6.82 16.11 3.64 5.33 3.56 2.84 1.57 1.96 Total Liabilities 923.92 820.28 734.77 445.46 336.43 253.06 245.40 241.34 231.19 175.61 Net Block 310.13 261.54 189.77 100.04 97.99 84.68 91.01 88.78 75.45 61.17 Gross Block 370.91 306.49 222.92 123.06 114.08 94.56 95.58 97.53 89.25 71.01 Accumulated Depreciation 60.77 44.95 33.14 23.03 16.08 9.88 4.57 8.75 13.80 9.84 Non Current Assets 523.43 355.39 237.22 180.00 138.44 120.39 125.82 126.31 102.29 72.55 Capital Work in Progress 148.82 67.63 43.41 78.79 40.21 35.35 34.38 35.58 25.18 10.96 Non Current Investment 63.80 25.30 0.05 0.05 0.05 0.05 0.12 0.10 0.10 0.10 Long Term Loans & Adv. 0.68 0.93 3.98 1.13 0.18 0.30 0.32 1.84 1.55 0.33 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 400.48 464.89 497.54 265.46 197.99 132.66 119.57 115.04 128.91 103.06 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 85.25 115.77 92.31 72.48 49.46 30.73 31.70 38.22 53.04 39.09 Sundry Debtors 111.68 84.66 115.18 73.50 52.49 59.95 53.40 49.61 42.34 35.36 Cash & Bank 74.96 157.58 227.91 89.28 1.54 1.73 2.73 5.58 7.09 5.06 Other Current Assets 128.59 17.25 13.28 4.01 94.51 40.25 31.74 21.63 26.44 23.55 Short Term Loans & Adv. 112.17 89.62 48.86 26.19 93.40 39.93 31.11 20.34 25.80 22.54 Net Current Assets 320.91 369.11 397.84 119.44 42.60 -2.25 -26.30 -29.11 -21.35 -11.82 Total Assets 923.91 820.28 734.76 445.46 336.43 253.05 245.39 241.35 231.20 175.61

Cash Flow

Standalone Figures in Rs. Crores

Right to Left

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 113.31 63.61 48.80 75.89 116.06 48.88 27.75 27.30 13.50 -6.25 PBT 165.69 123.49 207.24 167.31 96.23 57.10 14.46 8.06 8.06 10.16 Adjustment 2.40 4.61 6.87 5.39 10.24 12.67 15.78 16.47 13.30 8.84 Changes in Working Capital -17.14 -33.81 -104.35 -66.82 36.60 -6.80 0.80 2.87 -6.74 -24.61 Cash after chg. in Working capital 150.95 94.29 109.76 105.88 143.07 62.98 31.04 27.40 14.62 -5.61 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -37.65 -30.68 -60.96 -29.99 -27.00 -14.09 -3.29 -0.10 -0.46 -0.24 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.66 -0.40 Cash From Investing Activity -173.57 -123.65 -59.82 -46.80 -24.52 4.83 -4.71 -26.61 -32.83 -23.22 Net Fixed Assets -145.61 -107.79 -64.48 -47.56 -24.38 0.05 3.15 -18.68 -32.46 -23.95 Net Investments -38.50 -25.25 0.00 0.00 0.00 0.07 -0.02 0.00 0.00 -0.01 Others 10.54 9.39 4.66 0.76 -0.14 4.71 -7.84 -7.93 -0.37 0.74 Cash from Financing Activity -22.36 -10.28 149.65 -14.52 -29.23 -49.92 -20.01 -2.21 21.36 30.22 Net Cash Inflow / Outflow -82.63 -70.32 138.63 14.57 62.31 3.79 3.03 -1.51 2.03 0.75 Opening Cash & Equivalents 157.58 227.91 89.28 74.70 12.40 8.61 5.58 7.09 5.06 4.31 Closing Cash & Equivalent 74.96 157.58 227.91 89.28 74.70 12.40 8.61 5.58 7.09 5.06

Financial Ratios

Standalone

Right to Left

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 101.31 86.91 76.50 36.70 101.93 64.08 37.34 27.56 23.82 64.19 ROA 13.66% 11.56% 25.73% 31.61% 24.90% 15.82% 4.65% 2.40% 2.80% 5.37% ROE 15.73% 13.66% 34.34% 59.17% 60.42% 53.11% 22.16% 15.05% 17.20% 29.61% ROCE 22.31% 18.71% 43.34% 60.12% 49.67% 36.52% 18.63% 11.48% 12.27% 15.83% Fixed Asset Turnover 1.91 1.95 3.40 3.63 3.45 3.38 3.23 2.09 2.32 2.43 Receivable days 55.39 70.62 58.51 53.35 57.07 64.39 61.89 86.01 76.12 76.86 Inventory Days 56.71 73.53 51.10 51.64 40.70 35.46 47.13 85.36 90.25 84.22 Payable days 101.89 114.26 93.20 143.03 123.24 74.29 68.83 106.73 95.88 95.94 Cash Conversion Cycle 10.20 29.89 16.41 -38.04 -25.47 25.56 40.19 64.64 70.49 65.15 Total Debt/Equity 0.00 0.02 0.03 0.26 0.55 0.96 2.39 3.47 3.70 3.15 Interest Cover 33.18 41.04 50.37 42.01 15.05 6.59 2.34 1.69 1.80 2.47

Top Investors:

aditya birla sun life insurance company limited

cohesion mk best ideas sub-trust

hornbill orchid india fund

Annual Reports:

News Update:

Supriya Lifescience - Quarterly Results
24th Jan 2025, 16:24 PM

Read More
Supriya Lifescience strengthens position in international markets
9th Dec 2024, 15:12 PM

Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback